OPTN - Why ENT-Focused OptiNose Shares Are Diving Today | Benzinga
OptiNose, Inc. (NASDAQ: OPTN) shares are trading lower after the company announced a three-month extension of the FDA review period for the supplemental new drug application for XHANCE as a treatment for chronic rhinosinusitis.
The updated Prescription Drug User Fee Act (PDUFA) goal date is March 16, 2024.
XHANCE (fluticasone propionate) nasal spray is a drug-device combination product that combines the most widely used nasal anti-inflammatory drug with the innovative Exhalation ...